KR20100111691A - 의학 용도를 위한 5-o-치환 3-n-페닐-1,3,4-옥사디아졸론 - Google Patents
의학 용도를 위한 5-o-치환 3-n-페닐-1,3,4-옥사디아졸론 Download PDFInfo
- Publication number
- KR20100111691A KR20100111691A KR1020107015516A KR20107015516A KR20100111691A KR 20100111691 A KR20100111691 A KR 20100111691A KR 1020107015516 A KR1020107015516 A KR 1020107015516A KR 20107015516 A KR20107015516 A KR 20107015516A KR 20100111691 A KR20100111691 A KR 20100111691A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- aryl
- amino
- substituted
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US930207P | 2007-12-27 | 2007-12-27 | |
US61/009,302 | 2007-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20100111691A true KR20100111691A (ko) | 2010-10-15 |
Family
ID=40361548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107015516A KR20100111691A (ko) | 2007-12-27 | 2008-12-23 | 의학 용도를 위한 5-o-치환 3-n-페닐-1,3,4-옥사디아졸론 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2238131A1 (fr) |
JP (1) | JP2011507952A (fr) |
KR (1) | KR20100111691A (fr) |
CN (1) | CN101959881A (fr) |
AR (1) | AR069970A1 (fr) |
AU (1) | AU2008344032A1 (fr) |
BR (1) | BRPI0821482A2 (fr) |
CA (1) | CA2710743A1 (fr) |
CL (1) | CL2008003895A1 (fr) |
IL (1) | IL206419A0 (fr) |
MX (1) | MX2010006995A (fr) |
TW (1) | TW200932732A (fr) |
WO (1) | WO2009084970A1 (fr) |
ZA (1) | ZA201005306B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201028406A (en) * | 2008-12-23 | 2010-08-01 | Bial Portela & Ca Sa | 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use |
AR076687A1 (es) * | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen |
WO2010151160A1 (fr) * | 2009-06-24 | 2010-12-29 | Bial - Portela & Ca., S.A. | 3-n-hétéroaryl-1,3,4-oxadiazolones o substitué pour utilisation médicale |
US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
WO2011123719A2 (fr) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Utilisation d'inhibiteurs de faah pour le traitement des douleurs abdominales, viscérales et pelviennes |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3931843A1 (de) * | 1989-09-23 | 1991-04-04 | Bayer Ag | Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten |
DE19942354A1 (de) * | 1999-09-04 | 2001-03-08 | Aventis Pharma Gmbh | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln |
EP1448538A1 (fr) * | 2001-11-15 | 2004-08-25 | Eli Lilly And Company | Agonistes de recepteurs alpha actives de la proliferation des peroxysomes |
DE10208987A1 (de) * | 2002-02-28 | 2003-09-11 | Aventis Pharma Gmbh | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
EP1954137A4 (fr) * | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-ceto-oxazoles en tant que modulateurs d'amide d'acide gras hydrolase |
-
2008
- 2008-12-23 CA CA2710743A patent/CA2710743A1/fr not_active Abandoned
- 2008-12-23 CN CN2008801276810A patent/CN101959881A/zh active Pending
- 2008-12-23 KR KR1020107015516A patent/KR20100111691A/ko not_active Application Discontinuation
- 2008-12-23 BR BRPI0821482-4A patent/BRPI0821482A2/pt not_active IP Right Cessation
- 2008-12-23 TW TW097150238A patent/TW200932732A/zh unknown
- 2008-12-23 JP JP2010540610A patent/JP2011507952A/ja not_active Withdrawn
- 2008-12-23 AU AU2008344032A patent/AU2008344032A1/en not_active Abandoned
- 2008-12-23 WO PCT/PT2008/000054 patent/WO2009084970A1/fr active Application Filing
- 2008-12-23 CL CL2008003895A patent/CL2008003895A1/es unknown
- 2008-12-23 EP EP08866782A patent/EP2238131A1/fr not_active Withdrawn
- 2008-12-23 MX MX2010006995A patent/MX2010006995A/es not_active Application Discontinuation
- 2008-12-23 AR ARP080105707A patent/AR069970A1/es unknown
-
2010
- 2010-06-16 IL IL206419A patent/IL206419A0/en unknown
- 2010-07-26 ZA ZA2010/05306A patent/ZA201005306B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2011507952A (ja) | 2011-03-10 |
CA2710743A1 (fr) | 2009-07-09 |
CN101959881A (zh) | 2011-01-26 |
AU2008344032A8 (en) | 2010-08-19 |
MX2010006995A (es) | 2010-08-18 |
AR069970A1 (es) | 2010-03-03 |
BRPI0821482A2 (pt) | 2015-07-14 |
IL206419A0 (en) | 2010-12-30 |
WO2009084970A1 (fr) | 2009-07-09 |
ZA201005306B (en) | 2011-04-28 |
EP2238131A1 (fr) | 2010-10-13 |
CL2008003895A1 (es) | 2010-06-25 |
AU2008344032A1 (en) | 2009-07-09 |
TW200932732A (en) | 2009-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI676620B (zh) | 離胺酸特異性去甲基酶-1之抑制劑 | |
JP5525812B2 (ja) | Mekインヒビターとしての新規ヘテロアリール置換アリールアミノピリジン誘導体 | |
US9242977B2 (en) | Trk-inhibiting compound | |
CA2701053C (fr) | Derives de benzimidazole et d'indole substitues par de l'oxadiazole et oxazole comme inhibiteurs de dgat1 | |
US9624215B2 (en) | Amine derivative or salt thereof | |
JP2013047189A (ja) | 新規パラバン酸誘導体及びそれらを有効成分とする医薬 | |
US20100144733A1 (en) | Compounds, compositions and methods comprising heteroaromatic derivatives | |
KR101764608B1 (ko) | 산소-치환된 3-헤테로아로일아미노-프로피온산 유도체 및 약제로서의 이의 용도 | |
KR20170018079A (ko) | 히스톤 데메틸라아제 억제제 | |
TW201202198A (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
US20090203667A1 (en) | Pentadienamide derivatives | |
WO2012028629A1 (fr) | 2-(benzyloxy) benzamides en tant qu'inhibiteurs de la lrrk2 kinase | |
KR20100111691A (ko) | 의학 용도를 위한 5-o-치환 3-n-페닐-1,3,4-옥사디아졸론 | |
KR20120093428A (ko) | 스핑고신 키나아제 저해제 | |
US11584732B2 (en) | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | |
IL227025A (en) | Propionic acid derivatives are converted into the 3 heteroarylamino and used in pharmaceutical preparations | |
US9890117B2 (en) | Benzamide compounds and related methods of use | |
JP2020158391A (ja) | 新規ニトロカテコール誘導体 | |
US11597702B2 (en) | Substituted pyrazoles FFA4/GPR120 receptor agonists | |
WO2015170775A1 (fr) | Composé azole substitué et agent thérapeutique pour le diabète | |
WO2010074587A2 (fr) | 3-n-aryl-1,3,4-oxadiazolones 5-o-substituées destinées à une utilisation médicale | |
WO2010151160A1 (fr) | 3-n-hétéroaryl-1,3,4-oxadiazolones o substitué pour utilisation médicale | |
JP2013180955A (ja) | 組織トランスグルタミナーゼ阻害剤並びにカルコン誘導体及びその医薬用途 | |
WO2024137724A1 (fr) | Inhibiteurs de protéine tyrosine phosphatase, compositions et procédés d'utilisation | |
KR100954316B1 (ko) | 신규한 1-[1-(3,4-디알콕시벤질)-1h-피롤 화합물, 이의제조방법 및 이를 포함하는 천식 및 만성폐쇄성 폐질환을포함한 염증관련 질환, 관절염, 아토피 피부염, 암 및뇌질환의 치료 및 예방을 위한 약제학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |